Serina Therapeutics, Inc. Fair Value Adjustment of Warrants
Serina Therapeutics, Inc. (SER) reported Fair Value Adjustment of Warrants of -$50.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:FairValueAdjustmentOfWarrants · last filed 2026-08-13
- Serina Therapeutics, Inc. fair value adjustment of warrants for the quarter ending 2026-06-30 was -$50.00K, a 105.23% decline year-over-year.
- Serina Therapeutics, Inc. fair value adjustment of warrants for the quarter ending 2026-03-31 was -$104.00K.
- Serina Therapeutics, Inc. fair value adjustment of warrants for the quarter ending 2025-12-31 was -$3.19M.
- Serina Therapeutics, Inc. fair value adjustment of warrants for the quarter ending 2025-09-30 was -$1.04M.
- Serina Therapeutics, Inc. fair value adjustment of warrants for fiscal 2025 was -$4.26M.
- Serina Therapeutics, Inc. fair value adjustment of warrants for fiscal 2024 was -$13.16M.
- Serina Therapeutics, Inc. fair value adjustment of warrants for fiscal 2023 was -$1.08M, a 578.67% decline from fiscal 2022.
- Serina Therapeutics, Inc. fair value adjustment of warrants for fiscal 2022 was $225.00K.
| Period end | Fair Value Adjustment of Warrants 1 month | Fair Value Adjustment of Warrants 3 month | Fair Value Adjustment of Warrants 3 month as first filed | Fair Value Adjustment of Warrants 6 month | Fair Value Adjustment of Warrants 6 month as first filed | Fair Value Adjustment of Warrants 9 month | Fair Value Adjustment of Warrants 9 month as first filed | Fair Value Adjustment of Warrants 12 month | Fair Value Adjustment of Warrants 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$50.00K 10-Q · filed 2026-08-13 | -$154.00K 10-Q · filed 2026-08-13 | -$3.34M derived: sum of 3 quarters · filed 2026-08-13 | -$4.38M derived: sum of 4 quarters · filed 2026-08-13 | |||||
| 2026-03-31 | -$100.00K 10-Q · filed 2026-08-13 | -$104.00K 10-Q · filed 2026-05-14 | -$3.29M derived: sum of 2 quarters · filed 2026-05-14 | -$4.33M derived: sum of 3 quarters · filed 2026-05-14 | -$3.38M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | -$3.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | -$4.23M derived: sum of 2 quarters · filed 2026-03-25 | -$3.27M derived: sum of 3 quarters · filed 2026-08-13 | -$4.26M 10-K · filed 2026-03-25 | |||||
| 2025-09-30 | -$1.04M 10-Q · filed 2025-11-13 | -$88.00K derived: sum of 2 quarters · filed 2026-08-13 | -$1.08M 10-Q · filed 2025-11-13 | -$3.85M derived: sum of 4 quarters · filed 2026-08-13 | |||||
| 2025-07-31 | -$700.00K 10-Q · filed 2026-05-14 | ||||||||
| 2025-06-30 | $956.00K 10-Q · filed 2026-08-13 | -$33.00K 10-Q · filed 2026-08-13 | -$2.80M derived: sum of 3 quarters · filed 2026-08-13 | -$9.47M derived: sum of 4 quarters · filed 2026-08-13 | |||||
| 2025-03-31 | -$989.00K 10-Q · filed 2026-05-14 | -$3.76M derived: sum of 2 quarters · filed 2026-05-14 | -$10.43M derived: sum of 3 quarters · filed 2026-05-14 | -$19.72M derived: sum of 4 quarters · filed 2026-05-14 | |||||
| 2024-12-31 | -$2.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | -$9.44M derived: sum of 2 quarters · filed 2026-03-25 | -$18.73M derived: sum of 3 quarters · filed 2026-03-25 | -$13.16M 10-K · filed 2026-03-25 | |||||
| 2024-09-30 | -$6.67M 10-Q · filed 2025-11-13 | -$15.96M derived: sum of 2 quarters · filed 2025-11-13 | -$10.38M 10-Q · filed 2025-11-13 | -$21.56M derived: sum of 4 quarters · filed 2025-11-13 | |||||
| 2024-06-30 | -$9.29M 10-Q · filed 2025-08-11 | -$3.72M 10-Q · filed 2025-08-11 | -$14.89M derived: sum of 3 quarters · filed 2025-08-11 | -$15.49M derived: sum of 4 quarters · filed 2025-08-11 | |||||
| 2024-03-31 | -$5.58M 10-Q · filed 2024-08-09 | -$5.60M derived: sum of 2 quarters · filed 2025-03-24 | -$6.19M derived: sum of 3 quarters · filed 2025-03-24 | -$6.48M derived: sum of 4 quarters · filed 2025-03-24 | |||||
| 2023-12-31 | -$18.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | -$614.00K derived: sum of 2 quarters · filed 2025-03-24 | -$905.00K derived: sum of 3 quarters · filed 2025-03-24 | -$1.08M 10-K · filed 2025-03-24 | $35.00K 10-K · filed 2024-03-22 | ||||
| 2023-09-30 | -$596.00K 10-Q · filed 2024-11-12 | -$887.00K derived: sum of 2 quarters · filed 2024-11-12 | -$1.06M 10-Q · filed 2024-11-12 | $35.00K 10-Q · filed 2023-11-14 | -$1.05M derived: sum of 4 quarters · filed 2024-11-12 | ||||
| 2023-06-30 | -$291.00K 10-Q · filed 2024-08-09 | $5.00K 10-Q · filed 2023-08-14 | -$463.00K 10-Q · filed 2024-08-09 | $35.00K 10-Q · filed 2023-08-14 | -$458.00K derived: sum of 3 quarters · filed 2024-08-09 | -$493.00K derived: sum of 4 quarters · filed 2024-08-09 | |||
| 2023-03-31 | -$172.00K 10-Q · filed 2024-05-14 | $30.00K 10-Q · filed 2023-05-12 | -$167.00K derived: sum of 2 quarters · filed 2024-05-14 | -$202.00K derived: sum of 3 quarters · filed 2024-05-14 | -$34.00K derived: sum of 4 quarters · filed 2024-05-14 | ||||
| 2022-12-31 | $5.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-22 | -$30.00K derived: sum of 2 quarters · filed 2024-03-22 | $138.00K derived: sum of 3 quarters · filed 2024-03-22 | $225.00K 10-K · filed 2024-03-22 | |||||
| 2022-09-30 | -$35.00K 10-Q · filed 2023-11-14 | $133.00K derived: sum of 2 quarters · filed 2023-11-14 | $220.00K 10-Q · filed 2023-11-14 | ||||||
| 2022-06-30 | $168.00K 10-Q · filed 2023-08-14 | $255.00K 10-Q · filed 2023-08-14 | |||||||
| 2022-03-31 | $87.00K 10-Q · filed 2023-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B |